Hologic Q3 2025 Earnings Report: Analyst Expectations and Stock Performance

Hologic, Inc. (HOLX) is set to report Q3 2025 earnings after the market closes on Wednesday, Jul. 30. Analysts expect an adjusted EPS of $1.05, down marginally from $1.06 in the year-ago quarter. For fiscal 2025, analysts project an adjusted EPS of $4.19, representing a 2.7% year-over-year increase. HOLX stock has declined 16.8% over the past 52 weeks. Analysts are moderately optimistic about HOLX's stock, with an overall "Moderate Buy" rating.

Hologic, Inc. (HOLX), a global medical technology company focused on women's health, diagnostics, and medical imaging, is set to report its Q3 2025 earnings after the market closes on Wednesday, July 30. Analysts expect an adjusted EPS of $1.05, a marginal decrease from the $1.06 reported in the year-ago quarter [2]. For fiscal 2025, analysts project an adjusted EPS of $4.19, representing a 2.7% year-over-year increase [2]. Despite these expectations, HOLX stock has declined 16.8% over the past 52 weeks, lagging behind both the S&P 500 Index's 11.6% gain and the Health Care Select Sector SPDR Fund’s 8.6% decline [2].

Analysts are moderately optimistic about HOLX's stock, with an overall "Moderate Buy" rating. Among the 19 analysts covering the stock, six recommend "Strong Buy," one suggests a "Moderate Buy," and 12 advise "Hold" [2]. The mean price target of $68.67 indicates a 6.3% potential upside from HOLX’s current price levels [2].

Recent developments have influenced HOLX's stock performance. On May 1, HOLX stock dropped 1.6% following the release of its Q2 2025 results, with revenue declining 1.2% year-over-year due to a decrease in breast health revenue [2]. Despite this, the company’s adjusted EPS for the quarter came in at $1.03, surpassing the consensus estimates marginally [2]. Additionally, private equity groups TPG and Blackstone approached Hologic with a buyout offer exceeding $16 billion, although the company rejected the nonbinding proposal [3]. This potential acquisition has drawn considerable attention, as it would represent one of the largest leveraged buyouts this year [3].

Citi, one of the analysts covering HOLX, upgraded the stock from Neutral to Buy, raising its price target to $80.00 from $60.00, citing attractive valuation and improving business fundamentals [3]. The firm expressed confidence in the recovery of HOLX’s Breast Health segment and highlighted that the company faces easier year-over-year comparisons in its Surgical and Skeletal Health businesses [3].

Evercore ISI Group analyst Vijay Kumar also maintained an "In-Line" rating for HOLX, raising the price target from $62.00 to $68.00, reflecting a positive outlook on HOLX's market performance [4]. GuruFocus estimates the estimated GF Value for HOLX in one year to be $83.17, suggesting a potential upside of 29.21% from the current price of $64.37 [4].

Investors and financial professionals should closely monitor HOLX's Q3 2025 earnings report and the company's future developments to make informed investment decisions.

References:
[1] https://www.marketbeat.com/earnings/reports/2025-7-30-hologic-inc-stock/
[2] https://www.barchart.com/story/news/33414904/what-to-expect-from-hologic-s-q3-2025-earnings-report
[3] https://www.investing.com/news/analyst-ratings/citi-upgrades-hologic-stock-rating-to-buy-on-valuation-and-growth-outlook-93CH-4127714
[4] https://www.gurufocus.com/news/2963814/hologic-holx-price-target-raised-by-evercore-isi-group-holx-stock-news